NCT06099613View on ClinicalTrials.gov

Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

February 28, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

EG-COVII

EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants

Trial Locations (1)

3004

Nucleus Network Pty Ltd- Melbourne, Melbourne

Sponsors

Lead Sponsor

EyeGene Inc.
All Listed Sponsors
lead

EyeGene Inc.

OTHER

NCT06099613 - Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult | Biotech Hunter | Biotech Hunter